Preferred Label : Enasidenib Mesylate;
NCIt synonyms : Enasidenib Methanesulfonate; 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol
Methanesulfonate; 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-,
Methanesulfonate (1:1); AG-221 Mesylate;
NCIt definition : The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant
forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential
antineoplastic activity. Upon administration, enasidenib specifically inhibits various
mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits
the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular
differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor
cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers;
it initiates and drives cancer growth by blocking differentiation and the production
of the oncometabolite 2HG.;
UNII : UF6PC17XAV;
InChIKey : ORZHZQZYWXEDDL-UHFFFAOYSA-N;
CAS number : 1650550-25-6;
Drug name : Idhifa;
Molecule name : CC-90007; CC 90007;
NCI Metathesaurus CUI : CL524900;
Origin ID : C137825;
UMLS CUI : C4519427;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_component_of_chemotherapy_regimen
- is_salt_form_of
